Dechra Pharmaceuticals (LON:DPH) Hits New 52-Week Low at $2,473.32

Dechra Pharmaceuticals PLC (LON:DPH – Get Rating)’s share price hit a new 52-week low on Monday . The company traded as low as GBX 2,473.32 ($30.14) and last traded at GBX 2,480 ($30.23), with a volume of 64999 shares. The stock had previously closed at GBX 2,574 ($31.37).

Analyst Ratings Changes

A number of research firms recently issued reports on DPH. Jefferies Financial Group restated a “buy” rating and set a GBX 3,112 ($37.93) price objective on shares of Dechra Pharmaceuticals in a research report on Tuesday, February 28th. Berenberg Bank reissued a “hold” rating and set a GBX 2,850 ($34.73) price target on shares of Dechra Pharmaceuticals in a report on Monday, February 27th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Dechra Pharmaceuticals from GBX 4,600 ($56.06) to GBX 4,000 ($48.75) and set an “overweight” rating on the stock in a report on Tuesday, March 7th.

Dechra Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 60.73, a quick ratio of 1.66 and a current ratio of 2.73. The firm has a market capitalization of £2.95 billion, a P/E ratio of 7,377.14, a price-to-earnings-growth ratio of 1.42 and a beta of 0.71. The business has a fifty day moving average of GBX 2,867.69 and a 200-day moving average of GBX 2,819.92.

Dechra Pharmaceuticals Cuts Dividend

The firm also recently declared a dividend, which will be paid on Thursday, April 13th. Stockholders of record on Thursday, March 9th will be paid a GBX 12.50 ($0.15) dividend. The ex-dividend date of this dividend is Thursday, March 9th. This represents a dividend yield of 0.4%. Dechra Pharmaceuticals’s payout ratio is 12,857.14%.

About Dechra Pharmaceuticals

(Get Rating)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.